

Docket No. 22338-00444
U.S. Patent Application No. 10/617,573
Response to Restriction and Amendment
Amendment to the Claims:

Please amend the claims as follows:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1 to 60 (Cancelled)

Add new claims 61 to 83 as follows:

61. (New) A method of treating a degenerative cartilaginous disorder in a mammal comprising administering a therapeutically effective amount of an antagonist of a PRO10272 polypeptide to said mammal suffering from said disorder.
62. (New) The method of claim 61 wherein said polypeptide is the polypeptide of SEQ ID NO:6.
63. (New) The method of claim 61 wherein said polypeptide is encoded by ATCC deposit number PTA-11185.
64. (New) The method of claim 61 wherein said degenerative cartilaginous disorder is rheumatoid arthritis.
65. (New) The method of claim 61 wherein said degenerative cartilaginous disorder is osteoarthritis.
66. (New) The method of claim 61 wherein said degenerative cartilaginous disorder is psoriatic arthritis.

Docket No. 22338-00444

U.S. Patent Application No. 10/617,573

Response to Restriction and Amendment

67. (New) The method of claim 61 wherein said antagonist is an antibody.

68. (New) The method of claim 67 wherein said antibody is a monoclonal antibody.

69. (New) The method of claim 68 wherein said antibody is a human antibody.

70. (New) The method of claim 67 wherein said antibody is a humanized antibody.

71. (New) The method of claim 67 wherein said antibody is a chimeric antibody.

72. (New) A pharmaceutical composition for use in treating a degenerative cartilaginous disorder comprising an effective amount of the antagonist of claim 61 in admixture with a pharmaceutically acceptable carrier.

73. (New) The pharmaceutical composition of claim 72 wherein said composition also contains an immunosuppressant.

74. (New) The pharmaceutical composition of claim 73 wherein the immunosuppressant is methotrexate.

75. (New) A kit comprising a composition comprising an antagonist of the polypeptide of SEQ ID NO:6 in admixture with a pharmaceutically acceptable carrier, a container containing said composition and a label affixed to said container, or a package insert included in said container, referring to the use of said composition, in the treatment of a degenerative cartilaginous disorder.

76. (New) A method of treating a degenerative cartilaginous disorder comprising administering a therapeutically effective amount of an antagonist antibody wherein said

Docket No. 22338-00444

U.S. Patent Application No. 10/617,573

Response to Restriction and Amendment

antibody a) binds to a PRO10272 polypeptide having at least about 85% sequence identity to

SEQ ID NO:6 and b) inhibits the loss of cartilage.

77. (New) The method of claim 76 wherein said degenerative cartilaginous disorder is rheumatoid arthritis.

78. (New) The method of claim 76 wherein said degenerative cartilaginous disorder is osteoarthritis

79. (New) The method of claim 76 wherein said degenerative cartilaginous disorder is psoriatic arthritis.

80. (New) The method of claim 76 wherein the antibody is a monoclonal antibody.

81. (New) The method of claim 76 wherein said is a human antibody.

82. (New) The method of claim 76 wherein said antibody is a humanized antibody.

83. (New) The method of claim 76 wherein said antibody is a chimeric antibody.